John Katzenellenbogen News Today

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Less than 20% of diagnosed breast cancers are designated "triple-negative," lacking three types of receptors often found in other breast cancer types.

Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A high-fat diet further exacerbates the disease, which can progress to cirrhosis and liver failure.

URBANA, Ill. – Postmenopausal women have increased risk of non-alcoholic fatty liver disease due to loss of estrogen from metabolic changes. A

Markets Leerink Partners analyst Geoff Porges maintained a Hold rating on Radius Health (RDUS – Research Report) on April 22. The company’s shares closed last Friday at $20.90. According to TipRanks.com, Porges is a 3-star analyst with an average return of 5.9% and a 49.5% success rate. Porges covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Vertex Pharmaceuticals, and Theravance Biopharma. Radius Health has an analyst consensus of Moderate Buy, with a pric...

Seeing if Hormone Therapy Will Work for Breast Cancer Patients Only around half of the women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, blocks, or removes specific hormones to stall the growth and spread of breast cancer cells. The women who respond to these therapies are hormone receptor-positive, meaning that the breast tumor cells carry functional receptors for estrogen or progesterone or both.  The problem is that until now, there is no s...

An imaging test that measures the function of estrogen receptors in breast cancer cells can distinguish patients likely or unlikely to benefit from hormone therapy, a new study shows. Hormone therapy is commonly given as a targeted treatment for women whose cancer cells carry receptors for estrogen. But the therapy only works for about half of all patients. Until now, there hasn’t been a good way to reliably predict who will benefit and who will not. In a small phase 2 clinical trial, researc...

 E-Mail IMAGE: Bright spots indicate that cancer cells have responded to a one-day challenge with estrogen in this positron emission tomography (PET) scan of a woman with breast cancer. In a small... view more  Credit: Farrokh Dehdashti Hormone therapy commonly is given as a targeted treatment for women whose cancer cells carry receptors for estrogen. But the therapy only works for about half of all patients. Until now, there hasnt been a good way to reliably predict who will benefit an...